FDA’s Sachdev resigns
This article was originally published in The Tan Sheet
Deputy Commissioner for Policy Amit Sachdev formally resigns from the agency, Acting Commissioner Lester Crawford announces in an internal memorandum. Crawford cited Sachdev's work with Congress on FDA oversight, his contributions to expanding the agency's access to more resources for its various centers and leadership in speeding up review of medicines to treat HIV/AIDS under the White House's global AIDS initiative. Sachdev, whose last day was March 25, has not disclosed his future plans...
You may also be interested in...
The confirmation of FDA Commissioner Lester Crawford will allow for a reorganization of upper level management at the agency
Artificial intelligence model’s comments signal the likely start of computer-generated comments to the US FDA’s public notices.
Pink Sheet Podcast: US FDA Loses Gene Therapy Expert, Humira Biosimilars Launch, FDA Allows In-Person Meetings
Pink Sheet reporters and editors consider the impact of FDA Office of Tissues and Advanced Therapies Director Wilson Bryan’s retirement, the launch of Humira biosimilars and its effect on the biologic market, as well as the FDA moving to hybrid meetings with sponsors.